The ChemoStart Programme is an initiative by Insud Pharma, spearheaded by Leandro Sigman, to support innovative healthcare startups
In the second edition of the programme, 12 finalists have been shortlisted to present to a panel of experts at the Pitch Day on Thursday 31 January
The study of the brain and the way it works is becoming increasingly accessible as technology progresses and new tools are developed in the fields of neurology and psychiatry, among other sciences. The second edition of CNS Exeltis Day was organised with a view to pooling the wealth of existing knowledge on the brain and sharing both common and differential elements of neurology and psychiatry.
Two new grants for research into headaches and epilepsy were conferred within the framework of the 70th Annual Meeting of the Spanish Neurology Society (SEN). The research will seek to predict patients’ migraine attacks using markers and reduce the intensity and number of epileptic seizures. These grants not only represent an opportunity to enhance the quality of life of patients and their families, but will also promote research among young neurologists, encouraging doctoral training in the two fields.
Exeltis has received acceptance from the US Food and Drug Administration (FDA) of the filing of Slinda® (4mg Drospirenone-only pill), the novel oral contraceptive developed by the company. The Prescription Drug User Fee Act (PDUFA) date is expected during the 27 May of 2019.
This Friday, Exeltis teamed up with the National Resilience Institute to reward Irene Villa, Teresa Silva, Eduardo Palomino and María Carmen Villena, Maricruz Rubio and Diego Barreno for their outstanding ability to overcome adversity and their positive attitude to life.
A total of 42.7% of women would choose a flexible extended regimen in order to reduce and have greater control over their menses, according to the Flexo study undertaken by a team of Spanish scientists in cooperation with the Spanish Contraception Society.
The pharmaceutical group Insud Pharma has just kicked off the second round of its startup programme #CHEMOSTART!, which aims to help get innovative health projects off the ground and offer additional support to projects which are already up and running.
Through an agreement with Devicare, Exeltis Spain is to commercialise Lit-Control, a first-in-class medical solution which monitors urinary pH levels to treat recurring urinary diseases, such as renal lithiasis
Renal lithiasis alone affects 2.2 million people in Spain, with 325,000 new cases diagnosed every year, and is known for causing acute bouts intense pain (renal colic)
Exeltis and the entire Insud Pharma group have once again been rated “very good” in the 2017-2020 edition of the Spanish government’s Profarma Programme, thanks to our contribution to modernising the sector, our commitment to R&D and our clear focus on activities that add value.
The Autonomous University of Madrid (UAM) and the multinational pharmaceutical company Insud Pharma are launching the UAM-Insud Pharma Programme of Innovation Challenges with a Strong Social Impact for biomedical innovation with an open innovation approach that enables the transfer of knowledge through science excellence to overcome some of the specific challenges of our society.